July 21, 2023
The agency proposes significant revisions to oversight programs for drugs and medical products.
July 10, 2023
The confirmatory study—which tracked 18 months of data—helped clear the way for new Alzheimer’s drug.
June 06, 2023
Indicates that reimbursement for new slate of Alzheimer’s treatments will occur only with the completion of studies to support full approval.
May 25, 2023
Agency hopes to update and improve its advisory committee composition and operations—to help FDA scientists “get the best advice possible.”
May 03, 2023
Agency seeks added resources and new approaches to accelerate more of these promising treatments to the market.
April 24, 2023
The Supreme Court’s emergency action maintaining access to mifepristone fails to protect agency from future rulings that could subvert drug approval process.